$0.35
+0.03 (+9.27%)
Open$0.31
Previous Close$0.32
Day High$0.35
Day Low$0.30
52W High$47.16
52W Low$17.34
Volume—
Avg Volume454.4K
Market Cap25.18M
P/E Ratio44.64
EPS$0.71
SectorBiotechnology
Analyst Ratings
Buy
12 analysts
Price Target
+10,408.6% upside
Current
$0.35
$0.35
Target
$36.78
$36.78
$22.85
$36.78 avg
$42.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 16.46M | 14.50M | 15.97M |
| Net Income | 527.9K | 404.7K | 468.6K |
| Profit Margin | 3.2% | 2.8% | 2.9% |
| EBITDA | 822.7K | 875.9K | 889.3K |
| Free Cash Flow | 305.6K | 207.6K | 283.2K |
| Rev Growth | +9.2% | +19.8% | +5.1% |
| Debt/Equity | 1.41 | 1.41 | 1.44 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |